Tracking hantavirus nucleocapsid protein using intracellular antibodies
- 3.6k Downloads
Hantavirus nucleocapsid (N) protein is a multifunctional viral macromolecule involved in multiple stages of the viral replication cycle. The intracellular trafficking of N protein during virus assembly remains unclear.
We used N protein-specific intracellular expressed antibodies to track the localization and distribution of Hantaan virus and Seoul virus N protein. The N protein-specific antibody single-chain variable antibody fragments (scFvs), which bind an N-terminal linear epitope (L13F3) and C-terminal conformational domain (H34), were intracellularly expressed in the endoplasmic reticulum (ER) by fusion of the SEKDEL retention signal peptide at the carboxyl terminus, and in the cytoplasm (Cyto) by deletion of the ER membrane target signal peptide. Stable Vero-E6 cell lines expressing intracellular scFvs were either infected with hantavirus or transfected with an N protein expression plasmid; virus replication and N protein intracellular localization were determined.
N protein co-localized with scFvs in the ER and cytoplasm with or without viral membrane glycoproteins. Hantavirus replication was inhibited in both the scFvs-ER- and scFvs-Cyto-expressing stable cell lines.
N protein may be expressed in the ER retention signal peptide of KDEL circulating region (ER/cis-Golgi) without the assistance of G protein, and so expression of N protein in both the cytoplasm and within the ER/cis-Golgi plays an important role in virus replication.
KeywordsscFv Antibody scFv Gene Intracellular Antibody Seoul Virus Variable Antibody Fragment
Hantaviruses are members of the Bunyaviridae family, which contain three negative-sense, single-stranded RNA genome segments designated large (L), medium (M), and small (S) . The S, M, and L segments encode the nucleocapsid protein (N), glycoproteins (Gn and Gc), and L protein (an RNA-dependent RNA polymerase), respectively. Hantaviruses do not have matrix proteins, but the N protein has been proposed to play a key role in virus assembly . N protein is expressed in the cytoplasm, viral glycoproteins are co-translated in the endoplasmic reticulum (ER), once cleaved, Gn and Gc undergo glycosylation, folding, and heterodimerization in the Golgi complex, where they are retained and accumulate. For assembly to occur, N as well as Gn and Gc, must move to the same intracellular location. After interaction of N protein with viral RNA and subsequent assembly, ribonucleoprotein (RNP) is targeted to the Golgi complex by specific recognition of the cytoplasmic tail of Gn and Gc protein , the interaction of Gn protein cytoplasmic tail and the middle domain of the N protein was suggested to play essential role to direct RNPs to the site of the virus assembly  and the complete hetero-oligomeric (Gn-Gc) spike complex of hantaviruses might mediates the packaging of RNP into virions .
N protein has an intrinsic RNA chaperone activity, which is important for encapsidation and genome replication [6, 7]. The RNA-binding domain of N protein is situated within a central conserved region between residues 175 and 217 . The 141 residues proximal to the C-terminal are required for Golgi localization . Both N- and C-terminal regions have been implicated in homotypic N protein interaction, and putative coiled-coil motifs in the N-terminal region of N protein have been proposed to facilitate trimerization [10, 11, 12]. N was not observed in the Golgi so far, but it could be observed to surround the Golgi after infection [13, 9] and it was shown that targeting of N protein to the ER/Golgi intermediate compartment (ERGIC), prior to its movement to the Golgi compartment, and an intact ERGIC are necessary for viral replication . However, the impact of N protein intracellular trafficking on the cell and its effect on virus replication remain unclear. We used intracellular expression of anti-Hantaan virus (HTNV) and Seoul virus (SEOV) N protein N-terminal- and C-terminal-specific antibodies, respectively, to block or knock down N protein function at targeted sites, with or without co-expressed membrane glycoproteins, and assess the effect on virus replication and N protein intracellular trafficking. Our data showed that N protein co-localized with both cytoplasm and ER-retarded antibodies either with or without the help of G protein and virus replication was inhibited by related intracellular antibodies. These data suggest, therefore, that presentation of N protein both in the cytoplasm and within the ER/cis-Golgi plays an important role in hantavirus replication.
2. Materials and methods
2.1. Cells and antibodies
Vero-E6 cells, COS-7 cells, and a mouse hybridoma cell line L13F3 expressing mouse mAb binding to N protein of HTNV and SEOV (which targeted at a N-terminus epitope ) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with fetal calf serum (FCS; 10% v/v), penicillin (100 IU/ml), streptomycin (100 μg/ml), and L-glutamine complete (4.5 mM). The phage display-derived human Fab H34, which recognizes the HTNV N protein C-terminus conformational domain, was produced in our laboratory .
To construct single-chain fragment variable antibody fragments (ScFvs) specific for hantaviruses N protein, mRNA was isolated from ~1 × 106 L13F3 hybridoma cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA). The first cDNA strand was synthesized using SuperScript™reverse transcriptase (Invitrogen) according to the manufacturer's directions. L13F3 heavy chain (VH) variable region gene fragments were amplified using the forward primer 5'-GAATAGGCCATGGCGGAGGTCCAGCTGCAGGAGTCTGGGGGAGGCTTA G-3' and the reverse primer 5'-GGCCAGTGGATAAAGCTTTGGGGGTGTCGTTTTGGC-3'. Nco I and Hin dIII restriction sites were introduced at the 5'- and 3'-ends, respectively, of the VH gene using synthetic oligonucleotides. The L13F3 Vκ gene was PCR-amplified using a forward primer with the nucleotide sequence 5'-TACAGGATCCACGCGTAGACATTGTGATGACCCAGTCT-3' and a reverse primer of sequence 5'-TGACAAGCTTGCGGCCGCGGATACAGTTGGTGCAGCATC-3', containing MluI and NotI sites, respectively. PCR products were subsequently inserted into plasmid pOPE-101-215  between the restriction sites. The resulting plasmid was named pOPE-L13F3-scFv. As above, the H34-scFv-expressing plasmid pOPE-H34-scFv was constructed as follows: the H34 VH gene was amplified from the H34 Fab fragment using synthetic oligonucleotides with sequences 5'-GAATAGGCCATGGCGGAGGTGCAGCTGGAGTCT-3' and 5'-CAGTCAAGCTTTGATGAGACGGATACC-3', and Nco I and Hin dIII restriction sites were introduced at the 5'- and 3'-termini, respectively. The H34 VK gene was amplified using a forward primer with the nucleotide sequence 5'-TACAGGATCCACGCGTAGAAATTGTGTTGACGCAGTCTCCA-3' and the reverse primer 5'-TGACAAGCTTGCGGCCGCGAAGACAGATGGTGCAGCCACAGTTCGTCTG A-3', and MluI and NotI restriction sites were introduced at the 5'- and 3'-ends, respectively. PCR products were cloned into the plasmid pOPE-101-215.
To construct plasmids expressing intracellular scFvs in mammalian cells, the scFv gene (encoding a 6-histidine tag at the 3'-terminus) was PCR-amplified using the forward primers scFv-L13F3F-BssHII 5'-GGCGCGCACTCCGAGGTCCAGCTGCAGGAGTCTG-3', scFv-H34F-BssHII 5'-GGCGCGCACTCCGAGGTGCAGCTGGAGTCT-3' and the reverse primer scFv-R-XhoI 5'-CTCGAGATGATGATGGTGATGATGGGATAG-3' from plasmids pOPE-L13F3-scFv and pOPE-H34-scFv, respectively. Amplified fragments were cloned into pEF/myc/ER (Invitrogen) between the BssHII and XhoI restriction sites, producing the intracellular antibody expressing plasmids L13F3-scFv-ER and H34-scFv-ER. For the construction of plasmids L13F3-scFv-CYTO and H34-scFv-CYTO expressing cytoplasmic scFv, the scFv gene was prepared using NcoI/NotI from plasmids pOPE-L13F3-scFv and pOPE-H34-scFv and inserted into the pEF/myc/cyto vector (Invitrogen) between the Nco I and Not I restriction sites.
Plasmid pEF-N76118 was generated by amplifying the HTNV strain 76-118 N protein coding sequence using primers carrying adapters, and then cloned into pEF/myc/cyto and digestion with Nco I and Xba I.
The HTNV 76-118 N protein mammalian expression plasmid pEF-N76118 and intracellular antibody-expressing plasmids L13F3-scFv-ER, H34-scFv-ER, L13F3-scFv-CYTO, and H34-scFv-CYTO were transiently or stably transfected into eukaryotic cells. Plasmid DNA (3 μg or 1 μg) was coated onto the bottom of each well of a 6- or 24-well plate, respectively, using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. COS-7 cells were co-transfected with pEF-N76118 and one of the antibody-expressing plasmids. Cells were harvested 48 h after transfection. To generate cell lines for stable expression of antibodies, Vero E6 cells were transfected with scFv-expressing plasmids; cultures supplemented with G418 (500 μg/ml) were started 48 h after transfection. Mock-transfected cells died within 7 days in selective medium. Clones were isolated using the limited dilution method, dispensed into 96-well plates, and kept under selection pressure (G418; 500 μg/ml) for 14 days before reverting to normal culture medium. In this way, the antibody-expressing, stable Vero-E6 cell lines L13F3-scFv-ER-E6, H34-scFv-ER-E6, L13F3-scFv-CYTO-E6, and H34-scFv-CYTO-E6 were obtained.
2.4. Immunoblot assay
Immunoblots were used to confirm specificity of the recombinant scFvs. Routinely concentrated HTNV strain 76-118 and SEOV strain L99 prepared from Vero E6 cells (8 μl) were mixed with 5× SDS-PAGE Laemmli sample buffer [2 μl; 60 mM Tris-HCl (pH 6.8), 2% (w/v) SDS, 10% (v/v) glycerol, 5% (v/v) β-mercaptoethanol, and 0.01% (w/v) bromophenol blue]. Following denaturing at 95°C for 10 min, proteins were resolved on 12% (w/v) SDS-PAGE gels and electroblotted onto PVDF membranes. These membranes were rinsed with phosphate-buffered saline (PBS), blocked using 5% (w/v) skim milk powder in PBS (PBS-M) for 30 min, and probed with recombinant L13F3-scFv and H34-scFv (10 ml; 1 μg/ml) from XL1-Blue in PBS-M at room temperature (RT) for 2 h. After washing, the membrane was incubated in mouse anti-penta-His monoclonal antibody (1:1000 in PBS-M) for 1 h at RT. Membranes were then washed and incubated with goat anti-mouse IgG gamma chain-specific AP-conjugated antibody (1:1000 dilution in PBS-M) (Sigma) for 1 h at RT. After washing, membranes were developed in BCIP/NBT (Roth, Karlsruhe, Germany) substrate solution. All washes were performed thrice for 5 min each in 0.05% (v/v) PBS-T.
2.5. Enzyme-linked immunosorbent assay (ELISA)
To determine the concentration of viral particles in culture supernatants, group-specific L13F3 mouse anti-N mAb was coated onto 96-well microtiter plates overnight at 4°C. Coated plates were blocked with 5% (w/v) skimmed milk in PBS, and serial dilutions of detergent-treated culture supernatants were added. After washing, bound viral particles were detected by horseradish peroxidase-conjugated L13F3 mAb diluted 1:1000 in PBS-T. After washing three times with PBS-T, TMB peroxidase substrate [100 μl; dimethylformamide and hydrogen peroxide (H2O2)] was added and developed at RT for ~30 min. The reaction was stopped by adding H2SO4 (100 μl; 1 N). A450 (reference 620 nm) was read using a DTX 880 multi-mode detector (Beckman Coulter, Fullerton, CA, USA). The cutoff value was three standard deviations above the mean absorbance of the negative control wells.
2.6. Virus infection
HTNV strain 76-118 and SEOV strain L99 were propagated on Vero E6 cells. Cell cultures were harvested at 10 days postinfection; cell debris was removed by centrifugation at 4000 × g and samples stored in 1-ml aliquots at -80°C. Vero E6 cells and the intracellular antibody-expressing Vero-E6 cell lines L13F3-scFv-ER-E6, H34-scFv-ER-E6, L13F3-scFv-CYTO-E6, and H34-scFv-CYTO-E6 were cultured in T25 flasks to 85% confluence; cells were washed twice with pre-warmed serum-free DMEM and virus 76-118 and L99 were loaded at a multiplicity of infection (MOI) level of 0.01. Cells were then incubated at 37°C for 2 h. Cells were washed twice with pre-warmed serum-free DMEM and maintained in DMEM (5 ml) supplemented with 2% (v/v) FBS and incubated at 37°C for 8 days. Cell culture supernatants (1.0 ml) were collected each day after the third day postinfection and an identical amount of fresh medium was added. Viral antigen levels were assayed by ELISA using the L13F3 mAb, as described above. Supernatant Hantaviruses titers were determined by serially diluting supernatants of each virus stock and performing quadruplicate infections on Vero-E6 cells in 96-well plates. The TCID50 assay endpoint was determined on day 10. Used medium was discarded and cells fixed in 80% (v/v) ice-cold acetone. Viral antigen were detected by horseradish peroxidase conjugated L13F3 monoclonal antibody, TMB peroxidase substrate (Dimethylformamide and hydrogen peroxide) was added to develop color. Absorbance at 450 nm (reference 620 nm) was read with a DTX 880 multi-mode detector (Beckman Coulter). The cut-off value was determined by the 3 times SD above the mean absorbance of the negative control wells. And these were addressed at the part of methods. The TCID50 value was calculated by the method of Reed and Muench .
2.7. Immunofluorescence assay (IFA)
Specificity of the scFvs and intracellular distributions of N protein and intracellular scFvs were determined by indirect immunofluorescence assay (IFA). Hantaviruses-infected Vero E6 cells, stably transfected Vero E6 cells, or transiently transfected COS-7 cells were passaged onto sterile coverslips in six-well plates overnight. Cells were fixed by treatment with methanol for 10 min at -20°C followed by acetone for 10 min at -20°C. To eliminate nonspecific binding, cells were pre-incubated with PBS containing 5% (v/v) FCS for 30 min at RT in a humidity chamber. Antibody dilutions of 1:50 for H34 IgG, 1:100 for L13F3 mAb, 5 μg/ml of purified anti-N protein scFvs, and 1:200 for anti-penta-His mAb in PBS containing 5% FCS were used. The first round of incubation was carried out for 1 h at RT. For detection of bound, purified anti-N protein scFvs, the secondary antibody (mouse anti-His tag mAb) was loaded and incubated for 1 h. Antibodies were detected using either an antihuman fluorescein isothiocyanate (FITC)-conjugated secondary antibody or anti-mouse tetramethyl rhodamine isothiocyanate (TRITC)-conjugated antibody. Coverslips were washed in PBS, mounted on glass slides, and imaged under a TCS NT confocal microscope (Leica, Wetzlar, Germany).
2.8. His tag pull-down assay
About 5 × 107 HTNV-infected Vero E6 cells or the stably transfected cell lines L13F3-scFv-ER-E6, H34-scFv-ER-E6, L13F3-scFv-CYTO-E6, and H34-scFv-CYTO-E6 were harvested by centrifugation. Pellets were lysed in 1 ml ice-cold extraction buffer [TBS, pH 7.5; containing phenylmethylsulfonyl fluoride (1 mM), aprotinin (5 μg/ml), leupeptin (5 μg/ml), and 1% (v/v) Triton X-100] and gently rotated for 30 min. Samples were centrifuged at 4°C and 12,000 rpm for 10 min to remove cell debris. Ni-NTA His-bind resin (200 μl; Stratagene, La Jolla, CA, USA) was added and cleared supernatants were incubated at 4°C and 600 rpm in an Eppendorf thermomixer for 2 h. The resin was then harvested by centrifugation for 2 min at 4000 × g at 4°C and washed five times with 1 ml PBS and then five times with 1 ml PBS containing imidazole (20 mM). Bound proteins were eluted from the resin by incubation at 4°C in 500 μl PBS containing 500 mM imidazole. Pull-down elutes were stored at -80°C in 100-μl aliquots. Aliquots were concentrated by adding two volumes of ice-cold 100% ethanol and centrifuged at 10,000 × g for 10 min; pellets were resuspended in 10 μl dH2O followed by analysis by SDS-PAGE and immunoblotting with anti-penta-HIS (Qiagen, Hilden, Germany) and L13F3 N protein-specific mAbs as described above.
3.1. Intracellular expression of L13F3, H34 scFvs
Intracellular localization of scFvs was determined by indirect immunofluorescence. As expected, L13F3 and H34 scFvs-Cyto accumulated in the cytoplasm of transfected cells (Figure 1C, 1 and 2), while L13F3 and H34 scFvs-ER yield a typical ER specific morphological fluorescence image (Figure 1C, 3 and 4).
3.2. N protein interacted with intracellular antibodies in vivo
3.3. Hantavirus N protein co-localized with intracellular antibodies
3.4. Inhibition of N protein trafficking reduced HTNV replication
In this study, we demonstrated that N protein of Hantaan and Seoul virus localizes to the ER/cis-Golgi in the absence of membrane glycoproteins. Data further suggested that N protein co-localized with intracellular antibodies with the ER retention marker SEKDEL. In addition, analysis of antibody-expressing cell lines, infected with viruses, revealed that N protein trafficking to the ER/cis-Golgi is important for viral replication. Blocking of N protein trafficking at both the ER/cis-Golgi and in the cytosol leads to inhibition of replication.
The N protein is a 420-430 residue 50-kDa protein, the N-terminal 75 residues of which carry two coiled-coil motifs that facilitate trimerization and nucleocapsid protein trimers that are believed to be HTNV particle assembly intermediates [10, 11]. The L13F3 scFv antibody used in this study is known to bind to the N terminal 30 residues of N protein, which comprises part of the first coiled-coil motif . Additionally, H34 scFv has been shown to bind to a conformational epitope.
In hantaviruses, N protein is the first viral protein to accumulate during infection [13, 19, 20]. Viral RNA segments are complexed with N protein to form individual L, M, and S nucleocapsids , which are then packaged into the virion at the bilayered envelope within which are embedded the two viral surface glycoproteins Gn and Gc . The specific interaction between N protein and glycoprotein is thought to trigger budding of virions into the Golgi cisternae and to initiate the virus assembly[4, 5]. Although the laboratory evidences were presented recently, the precise mechanism of N protein entry into the ER/cis-Golgi apparatus remains unclear. ER-targeted scFvs used for tracking N protein intracellular trafficking were combined with a SEKDEL sequence at the carboxyl terminus. In mammalian cells, SEKDEL receptors are localized primarily to the early Golgi complex at steady state [22, 23], but shift in their localization upon binding of SEKDEL-bearing ligands . Therefore, we predicted that the ER-targeted scFvs would follow a route from the ER to the cis-Golgi and retrograde transport back to the ER. The co-localization and the proved interaction of N and ER-targeted intracellular antibodies indicate that N protein may entry into the ER/cis-Golgi apparatus. During virus infection, N protein or nucleocapsids also co-localized with ER-targeted antibodies. Virus replication was inhibited by the ER-targeted antibodies, which implies that N protein or nucleocapsids presented in membrane cisternae at the ER/cis-Golgi apparatus. Previous studies have shown that N protein is membrane-associated [9, 14], and that both targeting of N to ERGIC prior to its movement to the Golgi compartment and an intact ERGIC were required for viral replication . In membrane subcellular fractionation experiments, a small proportion of total N protein was detected in membrane-containing fractions . We hypothesize that N protein enters the ER or cis-Golgi apparatus, but only with low efficiency. An interaction between ER-targeted scFvs and membrane-associated N protein may act as a "motor" to enhance the entry of N protein into ER/cis-Golgi membrane vesicles. Like the function of the interaction of N protein and the cytoplasmic tail of Gn/Gc during virus replication [4, 5]. The ER provides a lower-energy environment than the Golgi system , which might enhance the entry of cytosol protein or nucleocapsids. The interaction between N and G protein is not the only prerequisite for the entry of N protein or cytosol nucleocapsids into membrane vesicles. Antibodies or other molecules might be alternative driver to direct the N protein to membrane vesicles. Immunoelectron microscopy examination of Uukuniemi virus, a bunyavirus, also demonstrated that the nucleocapsid is associated with membranes that show the characteristic distribution and tubulovesicular morphology of the pre-Golgi intermediate compartment, suggesting that the first site of formation of Uukuniemi virus particles is the pre-Golgi intermediate compartment and that virus budding continues in the Golgi stack .
In summary, the data we present in this study suggest that N protein may present in the ER/cis-Golgi without the assistance of viral G protein, and that N protein trafficking at these sites plays an important role in HTNV replication.
- 3.Pedersen R, Melin L: Synthesis, assembly and intracellulat transport of Bunyaviridae membrane proteins. In The Bunyaviridae. Edited by: Elliott RM. New York: Plenum press; 1996:159-188.Google Scholar
- 13.Kariwa H, Tanabe H, Mizutani T, Kon Y, Lokugamage K, Lokugamage N, Iwasa MA, Hagiya T, Araki K, Yoshimatsu K, Arikawa J, Takashima I: Synthesis of Seoul virus RNA and structural proteins in cultured cells. Archives of Virology 2003, 148: 1671-1685. 10.1007/s00705-003-0141-6PubMedCrossRefGoogle Scholar
- 14.Ramanathan HN, Chung D-H, Plane SJ, Sztul E, Chu Y-k, Guttieri MC, McDowell M, Ali G, Jonsson CB: Dynein-Dependent Transport of the Hantaan Virus Nucleocapsid Protein to the Endoplasmic Reticulum-Golgi Intermediate Compartment 10.1128/JVI.00418-07. J Virol 2007, 81: 8634-8647. 10.1128/JVI.00418-07PubMedPubMedCentralCrossRefGoogle Scholar
- 15.Bai X, Zhang Y, Wang Y, Pan L, Fack F, Bautz E: Fine mapping of epitopes of Hantaan virus nucleocapsid protein by peptides scanning. Journal of the Fourth Military Medical University 2000, 21: 36-41.Google Scholar
- 18.Reed LJ, Muench IL: A simple method for estimating fifty percent endpoints. American Journal of Hygiene 1938, 27: 493-497.Google Scholar
- 20.Schmaljohn CS: Bunyaviridae and their replication. In Virology. Edited by: Fields BN, Knipe DM, Howley PM. Philadelphia: Lippincott-Raven pub; 1996:1447-1471.Google Scholar
- 22.Lewis MJ, Pelham HRB: A human homologue of the yeast HDEL receptor. 1990, 348: 162-163.Google Scholar
- 23.Griffiths G, Ericsson M, Krijnse-Locker J, Nilsson T, Goud B, Soling H, Tang B, Wong S, Hong W: Localization of the Lys, Asp, Glu, Leu tetrapeptide receptor to the Golgi complex and the intermediate compartment in mammalian cells 10.1083/jcb.127.6.1557. J Cell Biol 1994, 127: 1557-1574. 10.1083/jcb.127.6.1557PubMedCrossRefGoogle Scholar
- 25.Sciaky N, Presley J, Smith C, Zaal KJM, Cole N, Moreira JE, Terasaki M, Siggia E, Lippincott-Schwartz J: Golgi Tubule Traffic and the Effects of Brefeldin A Visualized in Living Cells 10.1083/jcb.139.5.1137. J Cell Biol 1997, 139: 1137-1155. 10.1083/jcb.139.5.1137PubMedPubMedCentralCrossRefGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.